Diet Therapy Clinical Trial
Official title:
Mediterranean-like Unprocessed (CLEAN-MED) Diet Intervention Study of the Gut Microbiome of Healthy Adults
Background: Trillions of tiny organisms-including bacteria, fungi, and viruses-live inside our intestines. These microorganisms break down nutrients in our food, aid our immunity, and help keep us healthy. The population balances among these organisms can vary in different people due to factors including genetics, lifestyle, and diet. More studies are needed to understand how dietary habits affect our intestinal microorganisms. Objective: To see how switching from a traditional Western diet (low in fiber, high in saturated fat) to a Mediterranean-like unprocessed foods diet (CLEAN-MED) changes the environment in the intestine. The CLEAN-MED diet includes lots of vegetables, fruits, and whole grains with little sugar or red meat. Eligibility: Healthy adults aged 18 to 60 Design: Participants will be divided into 2 groups. All will start with a trial week. Participants will log all the food they eat and answer questions about their diet throughout the entire study. Participants in the short-term group will eat a Western diet for 4 weeks and a CLEAN-MED diet for 4 weeks. Food will be provided for the CLEAN-MED diet. Participants will visit the clinic each week and complete surveys. They will log everything they eat. They will provide blood, urine, and stool samples. Participants in the long-term group will eat the CLEAN-MED diet for up to 12 months. They will visit the clinic each month and complete surveys. They will log everything they eat. They will provide blood, urine, and stool samples. Some foods will be provided for the first 2 weeks. Participants may choose to have a scan of their body composition every few months.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | April 1, 2027 |
Est. primary completion date | April 1, 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | - INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: - Ability of subject to understand and the willingness to sign a written informed consent document - All genders, races, and ethnicities - Age 18-60, at the time of consent - Willingness to adhere to the dietary regimen and report any major stressors that occur during the study (i.e. changing jobs, moving, death of a close relative/friend, etc.) - Willingness to provide blood and stool specimens as specified - BMI >=18 and <= 35 kg/m^2 - Access to necessary resources for participating in a technology-based intervention: computer, smartphone, internet access, etc. - Has the ability/transportation methods to attend on-site visits - For 50 of the 60 participants in short-term cohort and for 40 of the 50 participants in the long-term cohort: Currently following a Western diet with PREDIMED-17 MedDiet score <= 7 for >= 1 months and a CLEAN-MED NOVA score of >= 35% kcal in NOVA 4 category with >= 14 items/week in NOVA 4 - For 10 of the 60 participants in short-term cohort and for 10 of the 50 participants in the long-term cohort: Currently following a Western diet with PREDIMED-17 MedDiet score <= 10 for >= 1 months and a CLEAN-MED NOVA score of >= 20% kcal in NOVA 4 category with >= 7 items/week in NOVA 4 - CLEAN-MED Logging Score of >= 43 after initial trial week to continue in the study for the randomization step - For long-term cohort only: Have resources and capability to consume freshly-cooked (i.e. not pre-packaged or frozen) meals EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study, at the discretion of the PI: - Current use of medications or dietary supplements for weight or appetite control, whether prescribed or not, including laxatives (within the last 4 weeks) - Currently eating a vegan, vegetarian, keto or other restrictive diet plan, or food allergies that would affect eating the study diet, at the discretion of the PI - Active cardiovascular disease (in past year with myocardial infarction, coronary stent or bypass surgery) - Diabetes (type 1 and 2) or history of gestational diabetes or on hypoglycemic medications or any other indication - Kidney disease (eGFR less than 50 mL/min per 1.73 m^2) - Liver disease (liver transaminase higher than 3 times the normal range for the laboratory) - Symptomatic gallstones - History of active cancer in the past 3 years except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision - Has a diagnosed autoimmune condition (i.e. HIV, lupus, etc.) or other immunosuppressive or immunodeficient state, at the discretion of the PI - Musculoskeletal disorders precluding regular physical activity - Consumption of the following drugs: proton pump inhibitors, antidiabetic drugs, cholesterol lowering drugs, SGLT-2 inhibitors, GLP-1 receptor agonist, insulin, Amylin analog, Alpha-glucosidase inhibitor, Dopamine agonist, Bile acid sequestrant, corticosteroids, methotrexate or immunosuppressive cytotoxic agents - Some types of abdominal surgery, including bariatric surgery, or severe intestinal problems (by discretion of study physician), including: - Inflammatory bowel disease (IBD) including ulcerative colitis (mild-moderate- severe), Crohn s disease (mild-moderate-severe), or indeterminate colitis; - Irritable bowel syndrome (IBS) (moderate-severe); - Persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated); - Chronic constipation - Consumes more than 3 alcoholic beverages per day - Currently receiving or has received antibiotics, antifungals, antivirals, or antiparasitics in past 2 months - Is currently using or has used probiotic supplements within the last 2 months - Is currently on a weight-loss program or has experienced a weight change (gain or loss) of greater than 15 pounds in the past 3 months - Has a history of hospitalization for mental health condition and/or has had a change in depression or anxiety prescription medications within the past 10 weeks (by discretion of study physician) - Is pregnant or breastfeeding or planning pregnancy within the time of the study - Subjects who are not fluent in English - Use of smoking or chewing tobacco, e-cigarettes, cigars, or other nicotine-containing products, or cannabis - Regular use of prescription opiate pain medication - Weight <100 lbs - Acute disease, defined as the presence of a moderate or severe illness with or without fever, at the time of enrollment - Inability to communicate effectively with study personnel - Lack of commitment with the intervention or non-compliance (at the discretion of the investigator) - Eating disorders |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institutes of Health Clinical Center (CC) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary objective is to assess changes in gut microbiome associated with a Mediterranean-like and unprocessed food diet compared to a habitual Western diet in healthy adults. | -Dietary intake via Dietary History Questionnaire (DHQ) III -PREDIMED MedDiet Score -Landry MedDiet Score -The CLEAN-MED NOVA score -Healthy Eating Index (HEI)-2015 -Weight change -Gut microbiome as measured by 16S rRNA analysis of frequent stool collections -Shotgun sequencing will include fungal and viral sequences -Microbial functional pathway analyses | 9 weeks (Short Term) 12 months (long Term) | |
Secondary | Measure biomarkers in various bodily specimens (stool, blood, etc.) using the pertinent biochemical assays. | 24 months | ||
Secondary | Identify associations between Mediterranean-like unprocessed food diet adherence with perceived quality of life. | -Daily assessment: CLEAN-MED Office for National Statistics (ONS) survey, 6 questions -Longer assessment: 36-Item Short Form Health Survey (SF-36) for health-related quality of life -Associations of changes in well-being with dietary patterns -Associations of changes in well-being with gut microbiota composition | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00687115 -
Predicting Weight Gain and Weight Loss Associated With Overeating or Fasting
|
Phase 2 | |
Completed |
NCT01237093 -
Developing Biomarkers of Dietary Intake
|
Phase 1 | |
Completed |
NCT01874106 -
Effect of Anti-inflammatory Diet on Inflammatory, Oxidative and Nutritional Markers in Hemodialysis Patients
|
N/A | |
Recruiting |
NCT05777746 -
The Effect of an Online Plant-Based Dietary Program on Cardiovascular Risk Factors in Persons With Type 2 Diabetes Mellitus: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT03341650 -
High Pasta vs. Low Pasta Diet in the Treatment of Obesity
|
N/A | |
Terminated |
NCT01083108 -
Effects of Caloric Restriction Alone Versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Metabolism in Patients With Diabetes Mellitus
|
Phase 2 | |
Completed |
NCT01812694 -
Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix
|
Phase 3 | |
Active, not recruiting |
NCT00410839 -
Studies of the Prevention of Atrial Fibrillation by ALA
|
Phase 2 | |
Completed |
NCT00410020 -
Arrhythmia Prevention With an Alpha-Linolenic Enriched Diet
|
Phase 2 | |
Recruiting |
NCT05256888 -
Time-Restricted Eating to Address Persistent Cancer-Related Fatigue
|
N/A | |
Recruiting |
NCT04799301 -
Developing Biomarkers of Dietary Intake: Dose Dependent Measurement of Sugar Intake
|
Phase 1 | |
Completed |
NCT00263172 -
Weight Loss on the Web: A Pilot Study Comparing a Commercial Website to a Structured Behavioral Intervention
|
N/A | |
Unknown status |
NCT00410722 -
Effect of Nuts vs. a Wheat Bran Muffin in Type 2 Diabetes
|
Phase 2 | |
Completed |
NCT00507520 -
Almond Dose Response Study.
|
Phase 2 | |
Completed |
NCT00430430 -
Lipoprotein Turnover on Low- and High-MUFA Portfolio Diets
|
Phase 2 | |
Active, not recruiting |
NCT00309439 -
ALA and Prostate Cancer
|
Phase 2 | |
Completed |
NCT00516594 -
The Effect of Altering Colonic Microflora After Fiber (FOS) Consumption
|
Phase 2 | |
Completed |
NCT00334308 -
Barley Protein and CVD
|
Phase 2 |